Get the Stockscreener App
27.52
0.15%
-0.04
After Hours:
27.58
0.06
+0.22%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $27.52, with a volume of 24.44M.
It is down -0.15% in the last 24 hours and up +2.04% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$27.56
Open:
$27.585
24h Volume:
24.44M
Relative Volume:
0.57
Market Cap:
$156.54B
Revenue:
$62.58B
Net Income/Loss:
$7.79B
P/E Ratio:
20.31
EPS:
1.3551
Net Cash Flow:
$9.08B
1W Performance:
+0.66%
1M Performance:
+2.04%
6M Performance:
+11.46%
1Y Performance:
+24.30%
1-Day Range:
$27.51
$27.84
1-Week Range:
$26.97
$27.84
52-Week Range:
$21.87
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.52 | 156.77B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
919.90 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
230.69 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
203.71 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.69 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
117.10 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer's Andrew Baum to Transition Role Amid Strategic Simplification - GuruFocus
CICC Initiates Coverage of Pfizer Inc. (PFE) With an Outperform Rating - Yahoo Finance UK
Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says - Reuters
Pfizer Inc. stock (US7170811035): Why does its post-COVID pivot matter more now for investors? - AD HOC NEWS
Mizuho reiterates BridgeBio stock rating ahead of Pfizer trial By Investing.com - Investing.com Canada
FDA Grants Priority Review for Pfizer and Astellas' Padcev with Keytruda for Bladder Cancer - Intellectia AI
Pfizer, Astellas win FDA priority review for Padcev (PFE:NYSE) - Seeking Alpha
Pfizer (PFE) and Amgen (AMGN) Expand Presence in Hong Kong - GuruFocus
Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP (PFE:NYSE) - Seeking Alpha
Seagen Inc (Acquired) stock (US8166361055): Why does its oncology pipeline still matter post-acquisi - AD HOC NEWS
Pfizer Impfstoff (Comirnaty): Post-Pandemic Revenue Drop Sparks Strategy Shift - AD HOC NEWS
Pfizer Impfstoff (Comirnaty): Post-Pandemic Pivot Challenges Traditional Vaccine Revenue - AD HOC NEWS
Where will Pfizer stock be in 3 years? - MSN
This Drug Stock Has Crushed the S&P 500 Over the Last Decade - The Motley Fool
Pfizer Inc. stock (US7170811035): Is its post-COVID pivot strong enough to unlock new upside? - AD HOC NEWS
Lobbying Update: $4,420,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Where Will Pfizer Stock Be in 3 Years? - Yahoo Finance
Pfizer’s COVID Reset Shifts Focus To Obesity Pipeline And Valuation Risks - simplywall.st
Pfizer (PFE) Valuation Check As COVID Decline And Obesity Pipeline Shift Reshape Its Outlook - Yahoo Finance
Mirae Asset Global Investments Co. Ltd. Acquires 177,689 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer (NYSE:PFE) Trading Up 1.3%What's Next? - MarketBeat
Wilson’s Disease Market to Reach New Heights by 2034 with Advancing Gene Therapies and Strong Pipeline from Vivet Therapeutics, Pfizer, and Ultragenyx Pharmaceutical | DelveInsight - Barchart.com
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Pfizer Patent Suits Seek to Block Competitors’ Dermatitis Drugs - Bloomberg Law News
Pfizer Impfstoff (Comirnaty): Post-Pandemic revenue drop raises big questions for Pfizer's future - AD HOC NEWS
Records Show Pfizer Used Sick Monkeys in Drug Testing, PETA Urges Review - PETA
Rebalancing Agents Hympavzi (Pfizer), Qfitlia (Sanofi), Alhemo (Novo Nordisk) Gain Ground in Hemophilia as Physicians Navigate Access Barriers and Expanding Treatment Complexity - Yahoo Finance
Pfizer (NYSE: PFE) CEO receives phantom stock unit award under deferred plan - Stock Titan
AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit - Yahoo Finance
Pfizer Stock: Painful Recovery Underway (NYSE:PFE) - Seeking Alpha
Wright Investors Service Inc. Purchases 56,743 Shares of Pfizer Inc. $PFE - MarketBeat
Meropenem Market Is Booming So Rapidly | Merck & Co. • Pfizer Inc. • AstraZeneca - openPR.com
Argo Wealth Advisory LLC Takes Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Acquired by AE Wealth Management LLC - MarketBeat
Pfizer (PFE) CEO Albert Bourla receives 911 phantom stock units as deferred pay - Stock Titan
Pfizer Inc (PFE) Stock Price, Trades & News - GuruFocus
Pfizer-Backed EV-209 Trial Targets Bladder Preservation in High-Need Cancer Segment - TipRanks
Pfizer stock price forecast: sideways trading expected as PFE consolidates above key supports - Traders Union
Here Are Thursday’s Top Wall Street Analyst Research Calls: Autoliv, CoreWeave, Corning, Dicks Sporting Goods, Federated Hermes, Gitlab, PayPal, Pfizer, Okta, and More - 24/7 Wall St.
Lbp Am Sa Has $25.32 Million Stake in Pfizer Inc. $PFE - MarketBeat
KBC Group NV Purchases 706,426 Shares of Pfizer Inc. $PFE - MarketBeat
CICC Initiates Pfizer at Outperform With $33 Price Target - marketscreener.com
Assessing Pfizer (PFE) Valuation As Investor Interest Returns And Turnaround Expectations Build - simplywall.st
DND Pharmatech Wins KRW1.83 Billion Anti-Obesity Drug Formulation Contract from Pfizer; Shares Rise 3% - marketscreener.com
New weight loss drug by Pfizer shows promising results in trial - AOL.com
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings - Yahoo Finance
How Biomarker Testing Helped a Lung Cancer Patient Get the Treatment She Needed - Pfizer
Pfizer Inc. $PFE Shares Sold by Freestone Capital Holdings LLC - MarketBeat
Pfizer Inc. stock (US7170811035): Is its wide moat strong enough to unlock new upside? - AD HOC NEWS
PFE Stock Quote Price and Forecast - CNN
Assetmark Inc. Has $62.58 Million Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):